DXCM DEADLINE ALERT: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM

Core Viewpoint - The Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][2]. Summary by Sections Class Action Details - Investors who purchased DexCom securities during the specified class period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025 [3]. Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom downplayed the severity of these issues, leading to increased regulatory scrutiny and potential legal repercussions [5].